80
Participants
Start Date
January 31, 2008
Primary Completion Date
November 30, 2010
Study Completion Date
November 30, 2010
erlotinib hydrochloride
PO 100 mg daily during WBRT, increasing to 150mg daily after WBRT for up to 24 months
placebo
WBRT plus matched placebo for the same schedule and duration as erlotinib hydrochloride
Charing Cross Hospital, London
University College of London Hospitals, London
Christie Hospital, Manchester
Salisbury District Hospital, Salisbury
Southampton General Hospital, Southampton
Glan Clwyd Hospital, Rhyl, Denbighshire
South West Wales Cancer Institute, Swansea
Collaborators (1)
Cancer Research UK
OTHER
Roche Pharma AG
INDUSTRY
University College, London
OTHER